HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results | Synapse
This research aims to assess the safety and efficacy of HPK1 inhibitor NDI-101150, both alone and in combination with pembrolizumab, in patients with advanced solid tumors.
Phase 1/2 trial design
Involves treatment with NDI-101150 and potential combination with pembrolizumab
Clinical registration number NCT05128487
Evaluation of T cell and dendritic cell interactions in the tumor microenvironment (TME)
Promising signals for continued drug development in treating advanced solid tumors
Resumen
T cells and dendritic cells in the TME, supporting continued development (clinical registration number NCT05128487).